{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:53Z","timestamp":1791919673698,"version":"4.3.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1053\/j.seminoncol.2012.02.006","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T20:52:23Z","timestamp":1337028743000},"page":"323-339","source":"Crossref","is-referenced-by-count":127,"title":["The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors"],"prefix":"10.1053","volume":"39","author":[{"given":"James W.","family":"Hodge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Ardiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Farsaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Kwilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia R.","family":"Gameiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2012.02.006_bib1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1039\/b911313b","article-title":"Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?","volume":"5","author":"Kamrava","year":"2009","journal-title":"Mol Biosyst"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.2922595","article-title":"Specific recognition of cruciform DNA by nuclear protein HMG1","volume":"243","author":"Bianchi","year":"1989","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib4","doi-asserted-by":"crossref","first-page":"17163","DOI":"10.1074\/jbc.M011547200","article-title":"Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules","volume":"276","author":"Binder","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.cdd.4401510","article-title":"Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: protection against radiation-induced effects and target structure for natural killer cells","volume":"12","author":"Gehrmann","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.it.2004.05.011","article-title":"The immune response under stress: the role of HSP-derived peptides","volume":"25","author":"Hickman-Miller","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1084\/jem.191.11.1965","article-title":"Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis","volume":"191","author":"Singh-Jasuja","year":"2000","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2174\/1381612023394089","article-title":"Immune modulation by ionizing radiation and its implications for cancer immunotherapy","volume":"8","author":"Friedman","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ijc.1020","article-title":"Ionizing radiation as a response-enhancing agent for CD95-mediated apoptosis","volume":"96","author":"Sheard","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2141.2000.01967.x","article-title":"Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells","volume":"108","author":"Vereecque","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib13","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1667\/RR0380.1","article-title":"Adhesion molecules in radiotherapy","volume":"166","author":"Baluna","year":"2006","journal-title":"Radiat Res"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.02.006_bib16","first-page":"53","article-title":"Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression","volume":"38","author":"Zamai","year":"1994","journal-title":"Eur J Histochem"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib17","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib18","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib20","first-page":"1462","article-title":"Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication","volume":"62","author":"Ganss","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0360-3016(02)03748-3","article-title":"Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis","volume":"54","author":"Brooks","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib22","first-page":"5150","article-title":"Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium","volume":"56","author":"Hallahan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2307\/3580044","article-title":"Accumulation of P-selectin in the lumen of irradiated blood vessels","volume":"152","author":"Hallahan","year":"1999","journal-title":"Radiat Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/ijc.11073","article-title":"Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat","volume":"105","author":"Ryschich","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1535-6108(02)00238-6","article-title":"Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels","volume":"3","author":"Hallahan","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib26","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","article-title":"Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer","volume":"11","author":"Gulley","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib28","first-page":"1031","article-title":"Samarium-153-EDTMP biodistribution and dosimetry estimation","volume":"34","author":"Eary","year":"1993","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.02.006_bib29","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1007\/s00259-004-1540-y","article-title":"153Sm-EDTMP for bone pain palliation in skeletal metastases","volume":"31","author":"Maini","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-008-0449-x","article-title":"Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects","volume":"57","author":"Chakraborty","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib32","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.169.7.3760","article-title":"Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo","volume":"169","author":"Grayson","year":"2002","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib33","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.2741\/2436","article-title":"Synergistic antitumor activity of immune strategies combined with radiation","volume":"12","author":"Sharp","year":"2007","journal-title":"Front Biosci"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib34","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1158\/1078-0432.CCR-08-0335","article-title":"The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing","volume":"14","author":"Chakraborty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib35","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1158\/1078-0432.CCR-04-2237","article-title":"The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors","volume":"11","author":"Kudo-Saito","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-05-1761","article-title":"Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis","volume":"12","author":"Gelbard","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib37","first-page":"1181","article-title":"The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma","volume":"7","author":"von Mehren","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-010-0005-5","article-title":"Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells","volume":"34","author":"Kaneno","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellimm.2010.03.001","article-title":"Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice","volume":"263","author":"Pfannenstiel","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1752-8062.2008.00070.x","article-title":"Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma","volume":"1","author":"Leao","year":"2008","journal-title":"Clin Transl Sci"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib44","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib45","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00262-011-1020-8","article-title":"Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses","volume":"60","author":"Gameiro","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood-2006-11-057935","article-title":"Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT","volume":"110","author":"Kochenderfer","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/smim.1997.0091","article-title":"Restoration of T-cell homeostasis after T-cell depletion","volume":"9","author":"Mackall","year":"1997","journal-title":"Semin Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib49","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-010-0930-1","article-title":"Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer","volume":"60","author":"Ramakrishnan","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1667\/RR1904.1","article-title":"Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse glioma model","volume":"173","author":"Newcomb","year":"2010","journal-title":"Radiat Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib53","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0022-5223(03)00707-4","article-title":"Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer","volume":"126","author":"Merritt","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0714.2006.00503.x","article-title":"Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines","volume":"36","author":"Sundelin","year":"2007","journal-title":"J Oral Pathol Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000012192","article-title":"Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells","volume":"59","author":"Matsuzaki","year":"2000","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib56","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002620100229","article-title":"Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes","volume":"50","author":"Bergmann-Leitner","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib57","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.bjc.6690449","article-title":"Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway","volume":"80","author":"Takizawa","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib58","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.mt.6300221","article-title":"Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus","volume":"15","author":"Song","year":"2007","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib59","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-08-0037","article-title":"Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination","volume":"14","author":"Tseng","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1158\/1078-0432.CCR-06-1838","article-title":"Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy","volume":"13","author":"Bae","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib61","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0169-5002(96)00559-4","article-title":"Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients","volume":"14","author":"Bretti","year":"1996","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2008.01.010","article-title":"Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale)","volume":"61","author":"Gebbia","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib63","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood.V90.9.3789","article-title":"Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells","volume":"90","author":"Hakim","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib64","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib66","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib67","first-page":"841","article-title":"Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells","volume":"27","author":"Law","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002620000122","article-title":"The immunological effects of taxanes","volume":"49","author":"Chan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e3181628b76","article-title":"Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes","volume":"31","author":"Markasz","year":"2008","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib70","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","article-title":"Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"2004","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib71","first-page":"7","article-title":"T regulatory cells, the evolution of targeted immunotherapy","volume":"1806","author":"Nizar","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib72","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00262-007-0305-4","article-title":"Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine","volume":"56","author":"Liu","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib73","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib74","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation","volume":"27","author":"Emens","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib75","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib76","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib77","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib78","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib79","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjc.6605206","article-title":"Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)","volume":"101","author":"Liu","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing towards the dream","volume":"3","author":"Arkin","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib83","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2012.02.006_bib84","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the BH3 domain to kill cancer cells","volume":"27","author":"Chonghaile","year":"2008","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib86","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","article-title":"Apoptosis-based therapies for hematologic malignancies","volume":"106","author":"Reed","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib87","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/17460913.2.6.605","article-title":"Anticancer and immunosuppressive properties of bacterial prodiginines","volume":"2","author":"Williamson","year":"2007","journal-title":"Future Microbiol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib88","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1078-0432.CCR-08-1575","article-title":"BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib90","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLML.2010.n.059","article-title":"Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis","volume":"10","author":"Parikh","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib91","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/leu.2008.175","article-title":"BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells","volume":"22","author":"Perez-Galan","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1755-8794-1-53","article-title":"A global transcriptional view of apoptosis in human T-cell activation","volume":"1","author":"Wang","year":"2008","journal-title":"BMC Med Genomics"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib93","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ijc.25177","article-title":"Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine","volume":"127","author":"Farsaci","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib94","first-page":"1837","article-title":"Vaccine therapy of established tumors in the absence of autoimmunity","volume":"9","author":"Hodge","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib95","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib96","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gde.2006.12.010","article-title":"KIT mutations in GIST","volume":"17","author":"Fletcher","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib98","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-004-3149-y","article-title":"The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels","volume":"7","author":"Osusky","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2010.02.004","article-title":"Targeting immune suppressing myeloid-derived suppressor cells in oncology","volume":"77","author":"Kao","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib101","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00262-009-0706-7","article-title":"Vaccination strategies in patients with renal cell carcinoma","volume":"58","author":"Asemissen","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib102","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib103","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1002\/ijc.26219","article-title":"Conseqence of dose scheduling of sunitinib on host immune response elements and vaccine combiantion therapy","volume":"130","author":"Farsaci","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib104","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib105","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6605083","article-title":"Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model","volume":"100","author":"Julien","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib106","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(06)00494-0","article-title":"A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy","volume":"176","author":"North","year":"2006","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib109","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3816\/CBC.2006.n.032","article-title":"A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229)","volume":"7","author":"Arlen","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib110","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib111","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","article-title":"A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer","volume":"12","author":"Arlen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib114","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-08-0276","article-title":"Combination chemotherapy and ALVAC-CEA\/B7.1 vaccine in patients with metastatic colorectal cancer","volume":"14","author":"Kaufman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00262-007-0428-7","article-title":"Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses","volume":"57","author":"Harrop","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib116","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1158\/1078-0432.CCR-07-0704","article-title":"Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses","volume":"13","author":"Harrop","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2012.02.006_bib117","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775412000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T17:16:47Z","timestamp":1594142207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775412000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0093775412000474"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2012.02.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}